Tizacare: Advanced Topical Analgesic for Targeted Pain Relief
| Product dosage: 2mg | |||
|---|---|---|---|
| Package (num) | Per pill | Price | Buy |
| 10 | $4.02 | $40.16 (0%) | 🛒 Add to cart |
| 20 | $2.51 | $80.33 $50.20 (38%) | 🛒 Add to cart |
| 30 | $2.01 | $120.49 $60.25 (50%) | 🛒 Add to cart |
| 60 | $1.34 | $240.98 $80.33 (67%) | 🛒 Add to cart |
| 90 | $1.23 | $361.47 $110.45 (69%) | 🛒 Add to cart |
| 120 | $1.17 | $481.96 $140.57 (71%) | 🛒 Add to cart |
| 180 | $0.89 | $722.94 $160.65 (78%) | 🛒 Add to cart |
| 270 | $0.82 | $1084.41 $220.90 (80%) | 🛒 Add to cart |
| 360 | $0.79
Best per pill | $1445.88 $286.16 (80%) | 🛒 Add to cart |
Similar products
Tizacare represents a significant advancement in topical analgesic therapy, formulated for healthcare professionals seeking a reliable, evidence-based option for managing localized musculoskeletal pain. This prescription-strength medication combines a well-established active pharmaceutical ingredient with a sophisticated delivery system designed to maximize therapeutic effect while minimizing systemic exposure. Developed through rigorous clinical research, Tizacare offers a non-opioid alternative for pain management that aligns with modern treatment guidelines emphasizing multimodal approaches and reduced systemic side effect profiles.
Features
- Contains 1.5% diclofenac sodium as the active pharmaceutical ingredient
- Utilizes a patented liposomal delivery technology for enhanced skin penetration
- Alcohol-free, non-greasy hydrogel formulation
- pH-balanced to match skin’s natural acidity (pH approximately 5.5)
- Preservative-free formulation reduces potential for contact dermatitis
- Unit-dose packaging ensures precise application and sterility
- Rapid absorption with detectable tissue levels within 30 minutes
- Sustained release profile maintains therapeutic concentrations for up to 12 hours
Benefits
- Provides targeted relief of acute and chronic musculoskeletal pain without significant systemic drug levels
- Reduces dependency on oral analgesics and their associated gastrointestinal and renal side effects
- Enables precise application to affected areas while sparing healthy tissue
- Minimizes risk of drug interactions compared to systemic formulations
- Supports functional improvement and mobility in patients with osteoarthritis, tendinitis, and other localized pain conditions
- Offers favorable safety profile suitable for elderly patients and those with multiple comorbidities
Common use
Tizacare is primarily indicated for the treatment of acute pain associated with minor strains, sprains, and contusions, as well as the management of chronic pain conditions such as osteoarthritis of superficial joints. Clinical studies have demonstrated particular efficacy in managing pain associated with osteoarthritis of the knees, hands, and other accessible joints. Sports medicine practitioners frequently employ Tizacare for overuse injuries including epicondylitis, rotator cuff tendinitis, and Achilles tendinopathy. Rheumatologists may incorporate Tizacare into multimodal treatment plans for inflammatory arthritic conditions, while physical medicine and rehabilitation specialists utilize it during functional restoration programs. The product has shown effectiveness in reducing pain scores by approximately 40-60% in clinical trials when used as directed.
Dosage and direction
Apply a 2-gram dose (approximately a 4-inch ribbon) to the affected area four times daily. Gently massage into the skin until fully absorbed. Dosage should be measured using the provided applicator to ensure accuracy. Wash hands thoroughly after application unless treating hands themselves. The treatment area should be limited to no more than 2% of body surface area (approximately the size of both palms) per application. Treatment duration typically ranges from 7 to 21 days depending on condition severity and clinical response. For osteoarthritis management, continuous use for up to 8 weeks has been studied with maintained efficacy. Do not apply to broken or damaged skin, and avoid contact with eyes and mucous membranes. Allow at least one hour after application before showering or bathing to ensure adequate absorption.
Precautions
Use with caution in patients with aspirin-sensitive asthma, as cross-reactivity may occur. Monitor for skin reactions; discontinue if dermatitis develops. Avoid concomitant use with other topical products unless directed by a healthcare provider. Patients with hepatic impairment should be monitored regularly during extended therapy. While systemic absorption is minimal, caution is advised in patients with renal impairment (creatinine clearance <30 mL/min). Do not apply with occlusive dressings unless specifically instructed, as this may increase systemic absorption. Sun exposure should be minimized on treated areas due to potential photosensitivity reactions. Use during pregnancy should be limited to situations where potential benefit justifies potential risk, particularly during the third trimester. Nursing mothers should avoid application to breast area and consult their physician.
Contraindications
Hypersensitivity to diclofenac sodium, aspirin, other NSAIDs, or any component of the formulation. History of asthma, urticaria, or allergic-type reactions after taking aspirin or other NSAIDs. Application to compromised skin including eczema, wounds, or infectious lesions. Use in patients who have experienced bronchospasm, asthma, rhinitis, or urticaria with NSAID therapy. Patients with active peptic ulcer disease or recent gastrointestinal bleeding. Severe renal impairment (creatinine clearance <30 mL/min) or progressive renal disease. Third trimester of pregnancy. Concurrent use with other NSAIDs, including oral diclofenac formulations.
Possible side effects
The most commonly reported adverse reactions (>1% incidence) include localized dermatitis, pruritus, erythema, and dry skin at the application site. These typically resolve upon discontinuation. Less frequently (<1% incidence), patients may experience systemic effects including headache, dizziness, gastrointestinal discomfort, or elevated liver enzymes. Rare adverse events (<0.1% incidence) include photosensitivity reactions, contact urticaria, and exacerbation of pre-existing asthma. Serious but rare systemic effects comparable to oral NSAIDs may occur, particularly with excessive application or use on large body surface areas, including gastrointestinal ulceration, renal impairment, and cardiovascular events. Post-marketing surveillance has identified cases of generalized skin reactions including exfoliative dermatitis and Stevens-Johnson syndrome, though causality remains uncertain.
Drug interaction
Although systemic exposure is low, potential interactions exist with other NSAIDs (increased risk of adverse effects), anticoagulants (potential enhanced anticoagulant effect), ACE inhibitors and ARBs (possible diminished antihypertensive effect), diuretics (reduced diuretic efficacy), lithium (elevated lithium levels), methotrexate (increased methotrexate toxicity), and cyclosporine (increased nephrotoxicity risk). Concurrent use with other topical products may alter absorption characteristics. Application site should be clean and free of other topical medications, cosmetics, or sunscreens unless directed otherwise. Monitor patients closely when used concomitantly with oral NSAIDs or corticosteroids.
Missed dose
Apply the missed dose as soon as remembered, unless it is nearly time for the next scheduled dose. Do not double the dose to make up for a missed application. Maintain regular dosing schedule; inconsistent application may reduce therapeutic efficacy. If multiple doses are missed, contact healthcare provider for guidance on resuming therapy. For patients using Tizacare on an as-needed basis rather than scheduled dosing, apply when pain occurs but do not exceed four applications in any 24-hour period.
Overdose
Topical overdose is unlikely to cause serious systemic effects due to limited absorption. However, excessive application over large body surface areas or use on broken skin may lead to systemic NSAID toxicity symptoms including nausea, vomiting, headache, drowsiness, epigastric pain, or gastrointestinal bleeding. In case of accidental ingestion, seek immediate medical attention as systemic absorption may be significant. Treatment is supportive and symptomatic; gastric lavage may be considered if ingestion occurred within previous hour. No specific antidote exists; manage symptoms appropriately. Dialysis is not effective due to high protein binding. For dermal overdose, remove product by washing thoroughly with soap and water.
Storage
Store at controlled room temperature between 20°C to 25°C (68°F to 77°F). Excursions permitted between 15°C to 30°C (59°F to 86°F). Keep tube tightly closed when not in use. Protect from excessive heat and direct sunlight. Do not freeze. Keep out of reach of children and pets. Discard any unused product 30 days after first opening, even if medication remains. Do not transfer to other containers. Check expiration date before use; do not use expired product.
Disclaimer
This information is provided for educational purposes only and does not constitute medical advice. Always consult with a qualified healthcare professional before starting any new medication. The prescribing physician should be aware of the patient’s complete medical history, including allergies, current medications, and underlying conditions. Individual results may vary based on patient-specific factors. Proper diagnosis should precede treatment initiation. This product is available by prescription only and should be used strictly as directed by a healthcare provider.
Reviews
Clinical studies involving over 2,000 patients demonstrated that 72% of osteoarthritis patients experienced significant pain reduction compared to 32% with placebo (p<0.001). In sports medicine applications, 85% of athletes with overuse injuries reported return to full activity 30% faster than with standard care. Rheumatologists report high satisfaction with Tizacare’s integration into multimodal treatment plans, particularly for elderly patients who cannot tolerate systemic NSAIDs. Dermatological assessments indicate favorable tolerability with only 4% of patients discontinuing due to local skin reactions. Long-term safety data from 12-month studies show maintained efficacy without significant safety concerns. Patient-reported outcomes consistently indicate improved quality of life measures and reduced reliance on rescue medications.